Hunterian Medicine is at the forefront of gene editing, leveraging a patented platform technology that enhances the delivery of CRISPR through a single adeno-associated virus (AAV). This innovative approach addresses a significant barrier in the field: the limited packaging capacity of AAV, which has historically restricted the effective delivery of CRISPR components. By utilizing a novel "2-for-1" genetic control element, specifically a bidirectional promoter, Hunterian Medicine has managed to condense the necessary instructions for CRISPR expression, allowing for efficient and targeted delivery. This advancement not only improves the safety and efficacy of CRISPR-based therapeutics but also expands the potential to develop treatments for a wide array of genetic disorders that currently lack FDA-approved therapies.

The technology developed by Hunterian Medicine enables researchers to target over a billion more regions in the human genome compared to existing methods, significantly broadening the scope of treatable genetic mutations. This capability is particularly crucial for addressing diseases that have historically been resistant to treatment, including various genetic disorders affecting skeletal and cardiac muscles, lungs, and the brain. Furthermore, the platform has demonstrated a reduction in off-target effects, enhancing the precision of gene editing. By overcoming the delivery challenges associated with traditional CRISPR systems, Hunterian Medicine is poised to accelerate the development of innovative therapies that could provide permanent cures for numerous genetic diseases.

United States

Headquartered in Cambridge, Massachusetts, Hunterian Medicine LLC is a gene-editing company working to cure genetic diseases by correcting DNA mutations using its innovative CRISPR delivery technology. The company’s patented technology solves the problem of CRISPR delivery with a “2-for-1” genetic element that enables delivery via a single adeno-associated virus (AAV).

Hunterian Medicine

Company Details